Positions

Investigator On

  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”)  awarded by THE WASHINGTON UNIVERSITY
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multicenter Study of Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease (“Protocol”).  awarded by Washington University
  • A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of 2 Potential Disease Modifying Therapies in Individuals at Risk for and with Dominantly Inherited Alzheimer’s Disease  awarded by Washington University
  • AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial)  awarded by University of Southern California
  • Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Project 1 & 2  awarded by University of California, San Francisco
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California
  • Alzheimer's Disease Cooperative Study - A4 Study  awarded by University of Southern California
  • Alzheimer's Disease Neuroimaging Initiative 3 (ADNl3)  awarded by University of Southern California
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)  awarded by University of Southern California
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study  awarded by University of Southern California
  • Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease(A4 Study)  awarded by University of Southern California
  • Combination Anti-Amyloid Therapy for Preclinical Alzheimer's Disease  awarded by University of Southern California
  • Exosome LRRK2 in Predicting Parkinson Disease Phenotypes  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Global Alzheimer’s Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease  awarded by University of Southern California
  • Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study A Companion Observational Study to Antl-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial  awarded by University of Southern California
  • Private Grant  awarded by EISAI, INC.
  • Private Grant  awarded by BIOGEN, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by NEURIM PHARMACEUTICALS
  • Private Grant  awarded by BIOGEN IDEC, INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by BIOGEN, INC.
  • Private Grant  awarded by BIOGEN MA INC
  • Private Grant  awarded by LILLY USA, LLC
  • Private Grant  awarded by Genentech
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by ATHIRA PHARMA
  • Tau PET Imaging for the USC Alzheimer's Therapeutic Research Institute (USC ATRI) A4 Trial (“A4 TAU”)  awarded by University of Southern California
  • The A3 Study: Ante-Amyloid Prevention of Alzheimer's Disease  awarded by University of Southern California
  • The Frontotemporal Lobar Degeneration Clinical Research Consortium  awarded by University of California, San Francisco
  • UAB Alzheimer's Disease Research Center  awarded by National Institute on Aging/NIH/DHHS
  • UAB Alzheimer's Disease Research Center - Clinical Core  awarded by NIH - National Institutes of Health/DHHS
  • Education And Training

  • Doctor of Medicine, University of Alabama at Birmingham 2013
  • Full Name

  • Bryan Smelser